about
A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.Acute clearance of human metapneumovirus occurs independently of natural killer cells.Border Patrol Gone Awry: Lung NKT Cell Activation by Francisella tularensis Exacerbates Tularemia-Like DiseaseLung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.Viral acute lower respiratory infections impair CD8+ T cells through PD-1Discovering naturally processed antigenic determinants that confer protective T cell immunity.Viral infection causes a shift in the self peptide repertoire presented by human MHC class I molecules.A Distinct Lung-Interstitium-Resident Memory CD8(+) T Cell Subset Confers Enhanced Protection to Lower Respiratory Tract InfectionMinor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand.Discovering protective CD8 T cell epitopes--no single immunologic property predicts it!Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus InfectionsEliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and Protocols.Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.Acute Viral Respiratory Infection Rapidly Induces a CD8+ T Cell Exhaustion-like Phenotype.Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication.Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.Fatty Acid-Mimetic Micelles for Dual Delivery of Antigens and Imidazoquinoline Adjuvants.Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus GlycoproteinAsymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan capPan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection SurvivorsIdentifying and Tracking Low-Frequency Virus-Specific TCR Clonotypes Using High-Throughput SequencingAntibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from SurvivorsEfficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman PrimatesIdentifying and Tracking Low-Frequency Virus-Specific TCR Clonotypes Using High-Throughput SequencingCross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalkAntibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus VaccineAnalysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus NeutralizationMucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T CellsPoly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccinesInfluenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in MiceHigh frequency of shared clonotypes in human B cell receptor repertoiresA Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer InterfaceNon-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other AntibodiesIntegrated technology platform for accelerated discovery of antiviral antibody therapeutics
P50
Q33775790-C8AD765F-D7BA-48CC-8C8D-359CC227C263Q34262084-9DEF0246-2244-4666-9467-324FDAE8DDDCQ35661972-FDBCC80A-929E-4263-AFF4-0307627188B7Q35913925-27CD645B-6551-41B8-A01F-0A8208AEB7B2Q36129102-833D642C-5CBC-4D96-8F51-992F63534E90Q36793499-D5DF6782-8337-409F-A933-7C5C2544D98FQ37035972-30230CB4-1B8B-4C7F-B4FC-1475BD03DB7CQ37253257-4816FC61-C9F6-4FEF-BA9F-ED08862CBE5FQ37771224-0B84D071-DB2C-41A6-B229-4ED8E00CAF3BQ38347244-6EEC0343-40BE-4282-A4D7-05A068F410AAQ40494092-32B91C7B-0468-484A-8DA3-A0EE580D2FA9Q40513167-6E2308E7-FCF6-46A6-824F-8AEE154D2CACQ40702974-C39A131F-8B3F-4480-B55D-7B0703BED368Q40984660-E6308261-89DA-4B92-8192-78EA9C735758Q41013010-32D46737-A335-479B-BD59-2667E8D0247FQ42136363-CB8A8B57-EA17-41CB-ACA8-DF9F7559ACDCQ42378276-39D161CF-BC22-4725-9B82-8EAAEE78FE38Q54218743-63452207-F10B-4CA7-ACE0-C845A77F0025Q55546673-DAE8AB79-4CEF-4C9D-879D-D0511390E9CDQ56897586-BD9A4293-308B-49C2-B5B7-0E8E88B5D678Q56999931-3A974191-5D2F-4D0B-942A-4EA98E829E11Q57092281-F65613B6-68D6-43F1-BE0C-5E5C729D8040Q59349752-444BB863-02B3-44D2-A296-C52B4379DDE8Q59354500-CDC665C6-D971-4624-8A8D-D70453253431Q59357446-EEC344A8-7482-4D9A-8F55-10C5225E3F75Q60227942-3E4F4591-55AE-427F-987C-3D113FDD2CB1Q64106080-58BB2F7D-A72E-4BA2-B1AC-B0AFB1F70FFBQ64360579-D14BE7BA-50B8-43A1-9002-8C4E0CAA8393Q89548894-E6148178-5C43-4957-8D5F-D2170C94C703Q90281326-845C6B6C-EA8A-4A47-8147-ABF650988F5FQ90942234-C16B75E1-B33A-4430-97B2-4F1A023B582FQ91403534-E4BBA9E5-CE73-4762-B9C5-847681611897Q91560038-D580F47A-578D-4ADA-A139-77684B8D1E10Q92114525-CBFD0EB7-914A-4CE1-A29F-D0B6CED26323Q93153131-15E7D81A-15E1-406D-A005-B98588380B09Q95601420-92536421-EA35-4F6F-8ADC-B8167BA58B6D
P50
description
immunology researcher
@en
name
Pavlo Gilchuk
@en
Pavlo Gilchuk
@nl
type
label
Pavlo Gilchuk
@en
Pavlo Gilchuk
@nl
prefLabel
Pavlo Gilchuk
@en
Pavlo Gilchuk
@nl